Clinical Trial Update: Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease [Phase 3]

View source ↗

Summary

This entry reports the completion of a Phase 3 long-term study of istradefylline in moderate to severe Parkinson's disease, with results posted on 2019-12-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease

Drugs mentioned

• Nourianz (istradefylline)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-12-13